Tag: 1334177-86-4

1334177-86-4, 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

The imine 17 (92 mg, 0.1 mmol, 1.1 equiv.) was dissolved in CHCI3 (6 ml.) with one drop of anhydrous MeOH to aid dissolution. Maleimide-PEG8-acid (53 mg, 0.09 mmol, 1 equiv.) was added followed by EEDQ (33 mg, 0.14 mmol, 1 .5 equiv.). This was left to stir vigorously at room temperature under Ar for 4 days until LC/MS analysis showed majority product formation. The solvent was removed in vacuo and the crude product was partially purified by silica gel column chromatography (CHCI3 with 1 % to 10% MeOH gradient) yielding 18 (81 mg). The material was purified further by preparative HPLC (method 2) to give 18 as a yellow solid (26.3 mg, 18%). Fast Formic run: LC/MS (method 3)(1 .39 min (ES+) m/z (relative intensity) 1485.00 ([M + H]+., 64).

As the paragraph descriping shows that 1334177-86-4 is playing an increasingly important role.

Reference£º
Patent; SPIROGEN SARL; HOWARD, Philip Wilson; WO2014/57072; (2014); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.

EDCI hydrochloride (8 mg, 0.042 mmol) was added to a suspension of Maleimide-PEG8-acid (25 mg, 0.042 mmol) in dry CH2Cl2 (4 mL) under argon atmosphere. PBD 85 (42 mg, crude) was added straight away and stirring was maintained until the reaction was complete (3 hours). The reaction was diluted with CH2Cl2and the organic phase was washed with H2O and brine before being dried over MgS04, filtered and excess solvent removed by rotary evaporation under reduced pressure by rotary evaporation under reduced pressure. The product was purified by careful silica gel chromatography (slow elution starting with 100% CHCI3 up to 9:1 CHCl3/MeOH) followed by reverse phase HPLC to remove unreacted maleimide-PEG8-acid. The product 86 was isolated in 10% over two steps (6.6 mg). LC/MS 1 .16 min (ES+) m/z (relative intensity) 770.20 ([M + 2H]+ , 40%).

The synthetic route of 1334177-86-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; VAN BERKEL, Patricius Hendrikus Cornelis; HOWARD, Philip Wilson; (281 pag.)WO2016/166341; (2016); A1;; ; Patent; VAN BERKEL, Patricius Hendrikus Cornelis; HOWARD, Philip Wilson; (280 pag.)WO2016/166307; (2016); A1;; ; Patent; VAN BERKEL, Patricius Hendrikus Cornelis; HOWARD, Philip Wilson; (280 pag.)WO2016/166300; (2016); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.

(d) 4-((2S, 5S) -37-(2, 5-dioxo-2, 5-dihydro- 1 H-pyrrol- 1 -yl) -5-isopropyl-2-methyl-4, 7, 35-trioxo- 10, 13, 16, 19, 22, 25, 28, 31 -octaoxa-3, 6, 34-triazaheptatriacontanamido)benzyl (3-(((S)-8-((5- (((S)- 7-methoxy-2-methyl-5-oxo-5, 11 a-dihydro- 1 H-benzo[e ]pyrrolo[1 , 2-a ][1 , 4 ]diazepin-8- yl)oxy)pentyl)oxy)-2-methyl-5-oxo-5, 11 a-dihydro-1 H-benzo[e]pyrrolo[1 ,2-a][1 ,4]diazepin-7- yl)oxy)propyl)carbamate (4) 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide (EDCI, 15 mg, 0.080 mmol, 1.1 eq) was added to a solution of crude 3 (0.077 mmol) and Mal-(PEG)8-acid (48 mg, 0.080 mmol, 1 .1 eq) in dry dichloromethane (2 ml_). The reaction was degassed three times with Argon and stirred for 2 hours and the presence of starting material was no longer observed by LC/MS. The reaction was diluted with dichloromethane and washed sequentially with water and brine. The organic phase was dried over magnesium sulphate filtered and excess dichloromethane removed by rotary evaporation under reduced pressure. The resulting residue was subjected to flash column chromatography (silica gel; 100% chloroform to 10% methanol in chloroform). Pure fractions were collected and combined and excess eluent was removed by rotary evaporation under reduced pressure to give the desired product (40mg). This residue was then purified further by preparative HPLC (3.7 mg, 31 % over 2 steps). LC/MS 1.40 min, (ES+) m/z (relative intensity) 1521.95 [M + H]+. 1H NMR (400 MHz, CDCI3) delta 8.72 (s, 1 H), 7.83 (s, 1 H), 7.80 (d, J = 3.9 Hz, 1 H), 7.63 – 7.61 (m, 2H), 7.47 (d, J = 8.3 Hz, 2H), 7.26 (br, 2H), 6.77 – 6.75 (m, 4H), 6.69 (s, 2H), 5.02 (s, 2H), 4.64 – 4.62 (m, 2H), 4.24 – 4.21 (m, 4H), 4.19 – 3.95 (m, 4H), 3.89 (s, 2H), 3.86 – 3.75 (m, 4H), 3.63 (br, 32H), 3.53 – 3.33 (m, 8H), 3.18 – 3.14 (m, 2H), 2.98 – 2.94 (m, 2H), 2.53 – 5.49 (m, 3H), 2.03 (s, 2H), 1.83 (br, 10H), 1 .56 (br, 2H), 1.42 (s, 3H), 1.05 – 0.90 (m, 6H).

The synthetic route of 1334177-86-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MEDIMMUNE LIMITED; HOWARD, Philip, Wilson; (203 pag.)WO2016/37644; (2016); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.

N-(3-Dimethylaminopropyl)-N?-ethylcarbodiimide (28 mg, 0.146 mmol, I eq) was added to asolution of 42 (203 mg, 0.146 mmol) and maleimide-PEG8 acid (87 mg, 0.146 mmol) inchloroform (5 mL). The reaction was stirred for 1.5 h then diluted with chloroform (50 mL), washed with water (50 mL), brine (30 mL), dried over magnesium sulphate, filtered and evaporated. Flash chromatography [gradient elution 100% DCM to 90% DCM/I0% methanol] gave 43 as a pale yellow solid (205 mg, 72%). LC/MS: RT 5.75 mm; MS (ES+)m/z (relative intensity) 982.90 (100), 1963.70 (5).

1334177-86-4 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid 51340955, apyrrolines compound, is more and more widely used in various.

Reference£º
Patent; SPIROGEN SARL; ADC THERAPEUTICS SARL; HOWARD, Philip Wilson; VAN BERKEL, Patricius Hendrikus Cornelis; WO2015/52534; (2015); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.

l-ethyl-3-(3′-dimethylaminopropyl)carbodiimide (EDCI, 33 mg, 0.172 mmol) was added to a solution of crude 63 (0.172 mmol) and Mal-(PEG)g-acid (100 mg, 0.172 mmol) in dry dichloromethane (10 mL). The reaction was stirred for 2 hours and the presence ofstarting material was no longer observed by LC/MS. The reaction was diluted with dichloromethane and washed sequentially with water and brine. The organic phase was dried over magnesium sulphate filtered and excess dichloromethane removed by rotary evaporation under reduced pressure. The resulting residue was subjected to flash column chromatography (silica gel; 100% chloroform to 10% methanol in chloroform). Pure fractions were collected and combined and excess eluent was removed by rotary evaporation under reduced pressure to give 64 (E) (60 mg, 25% over 3 steps).

1334177-86-4 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid 51340955, apyrrolines compound, is more and more widely used in various.

Reference£º
Patent; MEDIMMUNE LIMITED; LLOYD, Christopher O.; MARWOOD, Rose; HOWARD, Philip; HARPER, III, John W.; HOLLINGSWORTH, Robert; KAMAL, Adeela; DIMASI, Nazzareno; GAO, Changshou; TOADER, Dorin; WANG, Fengjiang; GINGIPALLI, Lakshmaiah; WO2015/155345; (2015); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

1334177-86-4, 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Piperidine (0.2 mL) was added to a solution of 90 (77 mg, 63.4 mumomicronIota) in DMF (1 mL). The reaction mixture was allowed to stir for 20 minutes. The reaction mixture was carefully diluted with DCM (50 mL) and washed with water (50 mL). The organic layers was washed with brine (100 mL), dried over MgSO4, filtered and evaporated under reduced pressure to provide the unprotected valine intermediate. The crude residue was immediately redissolved in chloroform (5 mL). Mal(Peg)8-acid (56 mg, 95 mumomicronIota) and EDCI (18 mg, 95 mumomicronIota) were added, followed by methanol (0.1 mL). The reaction was allowed to stir for 3 hours at room temperature at which point completion was observed by TLC and LC/MS (1 .19 min (ES+) m/z (relative intensity) 784.25 (([M + 2H] 2+)/2, 100)). The reaction mixture was diluted with chloroform (50 mL), washed with water (100 mL), dried (MgS04), filtered and evaporated in vacuo, followed by high vacuum drying, to provide the crude product. Purification by flash chromatography (gradient elution: HPLC grade 96:4 v/v CHCl3/MeOH to 90:10 v/v CHCl3/MeOH) gave 91 as a yellow solid (43 mg, 43%). 1H NMR (400 MHz, CDCI3) delta 8.73 (s, 1 H), 7.88 (dd, J = 7.6, 3.9 Hz, 2H), 7.75 (d, J = 8.6 Hz, 2H), 7.52 (d, J = 2.0 Hz, 2H), 7.44 (s, 1 H), 7.40 – 7.28 (m, 4H), 6.91 (d, J = 8.8 Hz, 2H), 6.81 (s, 2H), 6.69 (s, 2H), 6.48 (s, 1 H), 4.72 – 4.63 (m, 1 H), 4.46 – 4.34 (m, 2H), 4.25 – 4.03 (m, 6H), 3.95 (s, 4H), 3.84 (dd, J = 17.2, 10.1 Hz, 4H), 3.72 – 3.46 (m, 30H), 3.44 – 3.32 (m, 4H), 3.30 – 3.20 (m, 4H), 2.75 – 2.63 (m, 1 H), 2.59 (s, 4H), 2.55 – 2.43 (m, 3H), 2.37 (s, 3H), 2.29 (dd, J = 12.7, 6.7 Hz, 1 H), 2.03 – 1 .89 (m, 4H), 1 .72 (d, J = 22.7 Hz, 8H), 1 .46 (d, J = 7.2 Hz, 3H), 1 .01 (dd, J = 1 1 .5, 6.9 Hz, 6H). MS (ES+) m/z (relative intensity) 784.25 (([M + 2H] 2+)/2, 100).

1334177-86-4 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid 51340955, apyrrolines compound, is more and more widely used in various.

Reference£º
Patent; VAN BERKEL, Patricius Hendrikus Cornelis; HOWARD, Philip Wilson; (280 pag.)WO2016/166307; (2016); A1;; ; Patent; VAN BERKEL, Patricius Hendrikus Cornelis; HOWARD, Philip Wilson; (280 pag.)WO2016/166300; (2016); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

1334177-86-4, 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

EDCI.HCI (46 mg, 0.24 mmol) was added to a solution of 145 and Mal-PEG8-acid (130 mg,0.22 mmol) in CHCI3 (10 mL) and stirred at room temperature for 2 hr. LC/MS shows 78%starting material present. A further 2 eq EDCI.HCI was added in portions to push the reaction to completion. The reaction mixture was washed with water (10 mL), dried (Biotage PS) and evaporated to dryness, under reduced pressure, to leave a yellow solid which was purified by prep HPLC to leave the product I as an off-white solid (90 mg, 34%yield). LC/MS (method B): retention time 1.47 mins, (ES+) rnlz 1445.9 [M+ H].

1334177-86-4 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid 51340955, apyrrolines compound, is more and more widely used in various.

Reference£º
Patent; MEDIMMUNE LIMITED; HOWARD, Philip Wilson; GREGSON, Stephen John; (207 pag.)WO2018/192944; (2018); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.

Piperidine (0.2 mL) was added to a solution of 25 (77 mg, 63.4 pmol) in DM F (1 mL). The reaction mixture was allowed to stir for 20 minutes. The reaction mixture was carefully diluted with DCM (50 mL) and washed with water (50 mL). The organic layers was washed with brine (100 mL), dried over MgS04, filtered and evaporated under reduced pressure to provide the unprotected valine intermediate. The crude residue was immediately redissolved in chloroform (5 ml_). Mal(Peg)8-acid (56 mg, 95 pmol) and EDCI (18 mg, 95 pmol) were added, followed by methanol (0.1 ml_). The reaction was allowed to stir for 3 hours at room temperature at which point completion was observed by TLC and LC/MS (1.19 min (ES+) m/z (relative intensity) 784.25 (([M + 2H] 2+)/2, 100)). The reaction mixture was diluted with chloroform (50 ml_), washed with water (100 ml_), dried (MgS04), filtered and evaporated in vacuo, followed by high vacuum drying, to provide the crude product. Purification by flash chromatography (gradient elution: HPLC grade 96:4 v/v CHCI3/MeOH to 90:10 v/v CHCIs/MeOH) gave 26 as a yellow solid (43 mg, 43%). 1H NMR (400 MHz, CDCI3) delta 8.73 (s, 1 H), 7.88 (dd, J = 7.6, 3.9 Hz, 2H), 7.75 (d, J = 8.6 Hz, 2H), 7.52 (d, J = 2.0 Hz, 2H), 7.44 (s, 1 H), 7.40 – 7.28 (m, 4H), 6.91 (d, J = 8.8 Hz, 2H), 6.81 (s, 2H), 6.69 (s, 2H), 6.48 (s, 1 H), 4.72 – 4.63 (m, 1 H), 4.46 – 4.34 (m, 2H), 4.25 – 4.03 (m, 6H), 3.95 (s, 4H), 3.84 (dd, J = 17.2, 10.1 Hz, 4H), 3.72 – 3.46 (m, 30H), 3.44 – 3.32 (m, 4H), 3.30 – 3.20 (m, 4H), 2.75 – 2.63 (m, 1 H), 2.59 (s, 4H), 2.55 – 2.43 (m, 3H), 2.37 (s, 3H), 2.29 (dd, J = 12.7, 6.7 Hz, 1 H), 2.03 – 1 .89 (m, 4H), 1 .72 (d, J = 22.7 Hz, 8H), 1.46 (d, J = 7.2 Hz, 3H), 1 .01 (dd, J = 1 1 .5, 6.9 Hz, 6H). MS (ES+) m/z (relative intensity) 784.25 (([M + 2H] 2+)/2, 100).

1334177-86-4 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid 51340955, apyrrolines compound, is more and more widely used in various.

Reference£º
Patent; SPIROGEN SARL; HOWARD, Philip Wilson; TIBERGHIEN, Arnaud; CAILLEAU, Thais; WO2015/52321; (2015); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

1334177-86-4, 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

N-(3-Dimethylaminopropyl)-N?-ethylcarbodiimide (28 mg, 0.146 mmol, I eq) was added to asolution of 42 (203 mg, 0.146 mmol) and maleimide-PEG8 acid (87 mg, 0.146 mmol) inchloroform (5 mL). The reaction was stirred for 1.5 h then diluted with chloroform (50 mL), washed with water (50 mL), brine (30 mL), dried over magnesium sulphate, filtered and evaporated. Flash chromatography [gradient elution 100% DCM to 90% DCM/I0% methanol] gave 43 as a pale yellow solid (205 mg, 72%). LC/MS: RT 5.75 mm; MS (ES+)m/z (relative intensity) 982.90 (100), 1963.70 (5).

As the paragraph descriping shows that 1334177-86-4 is playing an increasingly important role.

Reference£º
Patent; SPIROGEN SARL; ADC THERAPEUTICS SARL; HOWARD, Philip Wilson; VAN BERKEL, Patricius Hendrikus Cornelis; WO2015/52533; (2015); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.

To a solution of 34 (337mg, 0.31 mmol) in dry CH2CI2 (5 mL) was added the PEG moiety (186 mg, 0.31 mmol) and EDCI.HCI (60 mg, 0.31 mmol). The mixture was stirred at room temperature under an atmosphere of argon until completion. The mixture wassubsequently diluted with CH2CI2 (50 mL) and washed with H20 (50 mL) and brine (50 mL) before removing the volatiles in vacuo. . The crude material was purified by silica gel column chromatography (CHCI3/MeOH ; 100% to 95:5) to afford pure product 35 as a light yellow foam (408.8 mg, 58% yield). Analytical Data: RT 1 .75 min; MS (ES+) m/z (relative intensity) 1643.15 {[M + H]+ , 10) 822.25 ([M + 2H]2+, 100).

As the paragraph descriping shows that 1334177-86-4 is playing an increasingly important role.

Reference£º
Patent; SPIROGEN SARL; HOWARD, Philip Wilson; WO2014/96365; (2014); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem